VYN 20 Pill - yellow capsule/oblong, 10mm
Generic Name: tafamidis
Pill with imprint VYN 20 is Yellow, Capsule/Oblong and has been identified as Vyndaqel tafamidis meglumine 20 mg. It is supplied by Pfizer Inc.
Vyndaqel is used in the treatment of Cardiomyopathy of Transthyretin-Mediated Amyloidosis; Transthyretin-Related Amyloidosis and belongs to the drug class transthyretin stabilizers. Vyndaqel tafamidis meglumine 20 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for VYN 20
Vyndaqel
- Generic Name
- tafamidis
- Imprint
- VYN 20
- Strength
- tafamidis meglumine 20 mg
- Color
- Yellow
- Size
- 10.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Transthyretin stabilizers
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Pfizer Inc.
- National Drug Code (NDC)
- 00069-1975
See also:
Vyndamax
Vyndamax may be given to reduce death or hospitalization caused by heart problems in adults with ...
Onpattro
Onpattro is used to treat polyneuropathy in adults with hereditary transthyretin-mediated ...
Tegsedi
Tegsedi (inotersen) is an RNA-targeting treatment that may be used to reduce the symptoms of ...
Wainua
Wainua (eplontersen) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Attruby
Attruby (acoramidis) tablets are used to treat cardiomyopathy of wild-type or hereditary ...
Vutrisiran
Vutrisiran (brand name Amvuttra) is used to treat nerve damage associated with hereditary ...
Acoramidis
Acoramidis is used for cardiomyopathy of transthyretin-mediated amyloidosis
More about Vyndaqel (tafamidis)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: transthyretin stabilizers
- En español
Patient resources
Other brands
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.